Tag: Oncology
-

GSK and Hansoh’s B7-H3 ADC Improves Progression-Free Survival in Phase 3 Osteosarcoma Trial
GSK and Hansoh’s B7-H3 ADC Ris-Rez improved progression-free survival in a Phase 3 osteosarcoma trial, while substantial toxicity remains a concern.
-

BMS’ RYZ101 Meets Phase 3 Endpoint in Neuroendocrine Tumors
BMS’ RYZ101 met its Phase 3 progression-free survival endpoint in neuroendocrine tumors after lutetium-177 therapy. Detailed efficacy and safety data remain pending.
-

Bristol Myers Squibb’s Zenbexus Cuts Progression or Death Risk by 51% in Phase 3 Trial
Bristol Myers Squibb’s Zenbexus regimen reduced the risk of progression or death by 51% and extended median progression-free survival to 42 months in Phase 3 EXCALIBER-RRMM.
-

Eli Lilly’s Jaypirca Wins FDA Approval for First-Line CLL/SLL
The noncovalent BTK inhibitor reduced the risk of progression or death by 80% versus bendamustine plus rituximab in previously untreated patients without known del(17p). Key Takeaways Data Snapshot Item Details Company Eli Lilly Drug Jaypirca (pirtobrutinib) FDA approval date October 2, 2026 Indication Previously untreated adult CLL/SLL without known del(17p) Pivotal trial Phase 3 BRUIN…
-

AbbVie’s Etentamig Cuts Progression or Death Risk by 60% in Phase 3 Multiple Myeloma Trial
AbbVie’s etentamig met both primary endpoints in the Phase 3 CERVINO trial, achieving a 74.0% objective response rate and reducing the risk of progression or death by 60% versus standard available therapies.
-

GSK Licenses HUTCHMED’s HMPL-A830 in a Deal Worth Up to $1.295 Billion
GSK licensed HUTCHMED’s preclinical HMPL-A830 for up to $1.295 billion, gaining ex-Greater China rights to a KRAS-EGFR antibody-targeted therapy conjugate designed to combine EGFR-guided delivery with intracellular KRAS inhibition.
-

Revolution Medicines Wins FDA Approval for Rasonque in Metastatic Pancreatic Cancer
The FDA approved Rasonque (daraxonrasib) for metastatic pancreatic adenocarcinoma after Phase 3 RASolute 302 showed a major survival benefit over chemotherapy.
-

Jazz Wins First-Line FDA Approval for Ziihera in HER2-Positive Gastroesophageal Cancer
The FDA approved Ziihera for first-line HER2-positive gastroesophageal adenocarcinoma, strengthening Jazz Pharmaceuticals’ solid-tumor oncology strategy.
-

Johnson & Johnson Wins EU Approval for Tecvayli Plus Darzalex in Multiple Myeloma
The European Commission approved Tecvayli plus Darzalex for adults with relapsed or refractory multiple myeloma after at least one prior therapy, supported by Phase 3 MajesTEC-3 data showing an 83% reduction in the risk of progression or death versus DPd or DVd.
-

Moderna’s Personalized mRNA Cancer Therapy Delivers First Phase 3 Win
Moderna and Merck’s personalized mRNA cancer therapy intismeran met both recurrence-free survival and distant metastasis-free survival endpoints in Phase 3 melanoma, marking a major milestone for individualized mRNA-based cancer treatment.